|
|
Benign Prostatic Hyperplasia: Expanding the drug treated populationPublished by: Datamonitor Published: Jun. 4, 2003 - 40 Pages Table of ContentsABOUT DATAMONITOR HEALTHCARE About the oncology pharmaceutical analysis team EXECUTIVE SUMMARY Scope Key findings for the BPH market DISEASE OVERVIEW Outline of the brief The prostate Development of BPH BPH and prostate cancer The mechanism of prostate growth Symptoms of BPH Diagnosis of BPH Epidemiology of BPH TREATMENT FOR BPH Watchful waiting Drug treatment Alpha-blocker therapy 5-á-reductase inhibitor therapy Combined alpha-blocker and 5-á -reductase inhibitor therapy Non-invasive surgical treatment of BPH Invasive surgical treatment Transurethral surgery Open surgery DRUGS IN DEVELOPMENT FOR BPH ML-04 Investigation of LHRH analogs in BPH APPENDIX Future readings R&D research methodology Introduction Hypothesis formulation Hypothesis testing Data verification and quality control OncoVision Bibliography How to contact experts in your industry Disclaimer AbstractIntroduction:Benign prostatic hyperplasia (BPH) is one of the most common benign tumors in men and is estimated to produce symptomatic disease in 40% of men over 60 years of age. The long-term solution of surgical intervention is more effective than current drug therapy, but the number of drug-treated patients could rise dramatically, from just 10%, as new types of drug reach late stage clinical development. Scope: * Overview of the disease pathology, presentation patterns and diagnosis * Detailed analysis of the treatment options a urologist uses to treat BPH * Review of the drugs currently in development for BPH Report Highlights: Alpha-blockers and 5alpha-reductase inhibitors are being combined to increase the efficacy of drug treatment for BPH, creating a niche for a co-packaged product. Phase II agent ML-04 has produced good efficacy and tolerability data, but Milkhaus still need a marketing partner to make the drug a success. The investigation of LHRH analogs in BPH may provide a route to prolonged patent protection for AstraZeneca’s Zoladex and Abbott/Takeda/TAP’s Lupron. Reasons to Purchase: * Define the underserved drug-treatable symptomatic BPH population and how to gain access to these patients * Identify the drug classes in development and to what degree they satisfy the unmet needs in the BPH market * Understand the current treatment patterns for BPH and how your product fits into the marketplace Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||